TSG6‐Exo@CS/GP Attenuates Endometrium Fibrosis by Inhibiting Macrophage Activation in a Murine IUA Model

• Published in: Advanced materials (Weinheim) Vol. 36; no. 21; pp. e2308921 - n/a
• Main Authors: Sun, Huijun, Dong, Jie, Fu, Zhaoyue, Lu, Xueyan, Chen, Xutao, Lei, Hui, Xiao, Xifeng, Chen, Shuqiang, Lu, Jie, Su, Danjie, Xiong, Yujing, Fang, Zheng, Mao, Jiaqin, Chen, Lihua, Wang, Xiaohong
• Format: Journal Article
• Language: English
• Published: Germany Wiley Subscription Services, Inc 01.05.2024
• Subjects: Endometrium; endometrium fibrosis; exosomes; Fibroblasts; Fibrosis; Infertility; Macrophages; stromal fibroblasts; Sustained release; TSG6; Tumor necrosis factor-TNF; TSG6; macrophages; endometrium fibrosis; exosomes; stromal fibroblasts
• ISSN: 0935-9648; 1521-4095
• DOI: 10.1002/adma.202308921

Intrauterine adhesion (IUA) is characterized by the formation of fibrous scar tissue within the uterine cavity, which significantly impacts female reproductive health and even leads to infertility. Unfortunately, severe cases of IUA currently lack effective treatments. This study presents a novel approach that utilizes tumor necrosis factor‐(TNF) stimulated gene 6 (TSG6)‐modified exosomes (Exos) in conjunction with an injectable thermosensitive hydrogel (CS/GP) to mitigate the occurrence of IUA by reducing endometrium fibrosis in a mouse IUA model. This study demonstrate that TSG6‐modified Exos effectively inhibits the activation of inflammatory M1‐like macrophages during the initial stages of inflammation and maintains the balance of macrophage phenotypes (M1/M2) during the repair phase. Moreover, TSG6 inhibits the interaction between macrophages and endometrial stromal fibroblasts, thereby preventing the activation of stromal fibroblasts into myofibroblasts. Furthermore, this research indicates that CS/GP facilitates the sustained release of TSG6‐modified Exos, leading to a significant reduction in both the manifestations of IUA and the extent of endometrium fibrosis. Collectively, through the successful construction of CS/GP loaded with TSG6‐modified Exos, a reduction in the occurrence and progression of IUA is achieved by mitigating endometrium fibrosis. Consequently, this approach holds promise for the treatment of IUA. The illustration depicts the therapeutic effectiveness of an injectable thermosensitive hydrogel (CS/GP) loaded with TSG6‐modified‐Exos in an intrauterine adhesion model. The TSG6‐Exo@CS/GP system enables sustained release of TSG6‐modified‐Exos, resulting in reduced levels of TGF‐β1 by inhibiting M1‐like macrophages and inhibiting alpha‐smooth muscle actin and collagen I expression owing to the activation of stromal fibroblasts, ultimately suppressing endometrium fibrosis.